Could there be a new study that opens the door for more effective and better
treatment options for
mesothelioma patients? Researchers have conducted a new study that promotes the assistance
of characterizing mutational profiles and the genetic discoveries of mesothelioma
in patients. The study showed over 2,500 alterations and 10 mutated genes
in patients.
According to the study, there were a large number of clinically actionable
mutations found in the patients. This means that there are options for
therapy and clinical trials designed to target the various mutations throughout
the body. In fact, some drugs and therapies currently available can target
the mutations found in the study because the targets are already found
in existing malignancies.
The research discovered a protein, PD-L1, in patients who have more aggressive
mesothelioma. Baylor College of Medicine has already began conducting
a trial in order to help create immunotherapy pathways to target PD-L1.
This protein is found in patients with pleural mesothelioma and knowing
that there may be an option to help with treatment is a big win for patients.
These findings are a positive sign for mesothelioma patients who may be
looking for alternative treatment options. Knowing the genetic basis of
mesothelioma means there are plenty of opportunities for clinical trials
to specifically target mutations and other genetic discoveries. This allows
for more effective therapy, better medication, and more.
Our mesothelioma attorneys at Worthington & Caron are dedicated to
helping patients who are enduring the hardships associated with mesothelioma.
If you have been diagnosed with mesothelioma, allow our team to work for
you and determine the cause. You may have legal options.
Call our firm today to speak with a legal professional about your potential claim to seek
compensation.